Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F16%3A33160464" target="_blank" >RIV/61989592:15110/16:33160464 - isvavai.cz</a>
Alternative codes found
RIV/75010330:_____/16:00011642
Result on the web
<a href="https://link.springer.com/article/10.1007%2Fs00280-016-3058-y" target="_blank" >https://link.springer.com/article/10.1007%2Fs00280-016-3058-y</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00280-016-3058-y" target="_blank" >10.1007/s00280-016-3058-y</a>
Alternative languages
Result language
angličtina
Original language name
Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
Original language description
Most patients with pancreatic ductal adenocarcinoma (PDAC) present with unresectable or metastatic disease with very poor prognosis. Chemotherapy is the primary treatment modality for patients with locally advanced and metastatic PDAC, but the efficacy of currently available regimens is limited. Taxanes are widely used in many primary cancers including breast, ovarian and lung cancers. The activity of combined regimen of taxanes plus nucleoside analogue or platinum derivate in terms of response rate ranges between 20 and 57 % in PDAC and may prolong overall survival. Since 2013 nab-paclitaxel (paclitaxel-albumin-bound particles) became a new treatment option for patients with metastatic pancreatic cancer based on the results of MPACT trial. Moreover, encouraging activity in PDAC of the combination regimen of paclitaxel and carboplatin that is being widely used in other solid tumors has been reported recently. Biomarkers, including biomarkers predictive of taxane resistance, could allow individualized tailored therapy. BRCA mutation status could serve as predictor of better chemotherapy treatment outcome in PDAC. The present review summarizes the principal clinical trials evaluating the efficacy of taxanes both as monotherapy and in combination in view of the potential use in the treatment of PDAC.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NV16-28375A" target="_blank" >NV16-28375A: Study of prognostic and predictive biomarkers in the treatment of pancreatic cancer</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancer Chemotherapy and Pharmacology
ISSN
0344-5704
e-ISSN
—
Volume of the periodical
78
Issue of the periodical within the volume
6
Country of publishing house
DE - GERMANY
Number of pages
11
Pages from-to
1101-1111
UT code for WoS article
000392322300001
EID of the result in the Scopus database
—